1
|
Nakajima R. Targeted Therapy for Prostate Cancer by Prostate-Specific Membrane Antigen-Targeted Small-Molecule Drug Conjugates. Chem Pharm Bull (Tokyo) 2024; 72:136-142. [PMID: 38296554 DOI: 10.1248/cpb.c23-00535] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2024]
Abstract
In the aging global population, prostate cancer is a worldwide health problem because the incidence rate of this disease increases at advanced ages. Although early-stage prostate cancer can be treated by total prostatectomy, the surgery causes side effects, such as incontinence and dysuria, that lower QOL. Once the disease progresses to metastatic castration-resistant prostate cancer (mCRPC), there are no effective chemotherapeutic agents without systematic side effects. Therefore, targeted therapies for mCPRC are urgently needed. Traditional antibody-drug conjugate treatments for prostate cancer have been tested in clinical trials and several side effects have been observed. Meanwhile, small-molecule drug conjugates (SMDCs) have certain advantages over antibody drug conjugates in terms of non-immunogenicity, reproducibility, and permeability. In this review, prostate-specific membrane antigen-targeted SMDCs for treating prostate cancer are summarized.
Collapse
Affiliation(s)
- Ryo Nakajima
- Department of Synthetic Organic Chemistry, Graduate School of Biomedical and Health Sciences, Hiroshima University
| |
Collapse
|
2
|
Murce E, Spaan E, Beekman S, van den Brink L, Handula M, Stuurman D, de Ridder C, Dalm SU, Seimbille Y. Synthesis and Evaluation of ePSMA-DM1: A New Theranostic Small-Molecule Drug Conjugate (T-SMDC) for Prostate Cancer. Pharmaceuticals (Basel) 2023; 16:1072. [PMID: 37630990 PMCID: PMC10458530 DOI: 10.3390/ph16081072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2023] [Revised: 07/21/2023] [Accepted: 07/25/2023] [Indexed: 08/27/2023] Open
Abstract
Small-molecule drug conjugates (SMDCs) are compounds in which a therapeutic payload is conjugated to a targeting vector, for specific delivery to the tumor site. This promising approach can be translated to the treatment of prostate cancer by selecting a targeting vector which binds to the prostate-specific membrane antigen (PSMA). Moreover, the addition of a bifunctional chelator to the molecule allows for the use of both diagnostic and therapeutic radionuclides. In this way, the distribution of the SMDC in the body can be monitored, and combination therapy regimes can be implemented. We combined a glutamate-urea-lysine vector to the cytotoxic agent DM1 and a DOTA chelator via an optimized linker to obtain the theranostic SMDC (T-SMDC) ePSMA-DM1. ePSMA-DM1 retained a high binding affinity to PSMA and demonstrated PSMA-specific uptake in cells. Glutathione stability assays showed that the half-life of the T-SMDC in a reducing environment was 2 h, and full drug release was obtained after 6 h. Moreover, 100 nM of ePSMA-DM1 reduced the cell viability of the human PSMA-positive LS174T cells by >85% after 72 h of incubation, which was comparable to a 10-fold higher dose of free DM1. [111In]In-ePSMA-DM1 and [177Lu]Lu-ePSMA-DM1 were both obtained in high radiochemical yields and purities (>95%), with >90% stability in PBS and >80% stability in mouse serum for up to 24 h post incubation at 37 °C. SPECT/CT imaging studies allowed for a faint tumor visualization of [111In]In-ePSMA-DM1 at 1 h p.i., and the ex vivo biodistribution showed tumor uptake (2.39 ± 0.29% ID/g) at 1 h p.i., with the compound retained in the tumor for up to 24 h. Therefore, ePSMA-DM1 is a promising T-SMDC candidate for prostate cancer, and the data obtained so far warrant further investigations, such as therapeutic experiments, after further optimization.
Collapse
Affiliation(s)
- Erika Murce
- Department of Radiology and Nuclear Medicine, University Medical Center Rotterdam, Erasmus MC, 3015 GD Rotterdam, The Netherlands; (E.M.); (E.S.); (S.B.); (L.v.d.B.); (M.H.); (D.S.); (C.d.R.); (S.U.D.)
- Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands
| | - Evelien Spaan
- Department of Radiology and Nuclear Medicine, University Medical Center Rotterdam, Erasmus MC, 3015 GD Rotterdam, The Netherlands; (E.M.); (E.S.); (S.B.); (L.v.d.B.); (M.H.); (D.S.); (C.d.R.); (S.U.D.)
- Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands
| | - Savanne Beekman
- Department of Radiology and Nuclear Medicine, University Medical Center Rotterdam, Erasmus MC, 3015 GD Rotterdam, The Netherlands; (E.M.); (E.S.); (S.B.); (L.v.d.B.); (M.H.); (D.S.); (C.d.R.); (S.U.D.)
- Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands
| | - Lilian van den Brink
- Department of Radiology and Nuclear Medicine, University Medical Center Rotterdam, Erasmus MC, 3015 GD Rotterdam, The Netherlands; (E.M.); (E.S.); (S.B.); (L.v.d.B.); (M.H.); (D.S.); (C.d.R.); (S.U.D.)
- Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands
| | - Maryana Handula
- Department of Radiology and Nuclear Medicine, University Medical Center Rotterdam, Erasmus MC, 3015 GD Rotterdam, The Netherlands; (E.M.); (E.S.); (S.B.); (L.v.d.B.); (M.H.); (D.S.); (C.d.R.); (S.U.D.)
- Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands
| | - Debra Stuurman
- Department of Radiology and Nuclear Medicine, University Medical Center Rotterdam, Erasmus MC, 3015 GD Rotterdam, The Netherlands; (E.M.); (E.S.); (S.B.); (L.v.d.B.); (M.H.); (D.S.); (C.d.R.); (S.U.D.)
- Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands
| | - Corrina de Ridder
- Department of Radiology and Nuclear Medicine, University Medical Center Rotterdam, Erasmus MC, 3015 GD Rotterdam, The Netherlands; (E.M.); (E.S.); (S.B.); (L.v.d.B.); (M.H.); (D.S.); (C.d.R.); (S.U.D.)
- Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands
| | - Simone U. Dalm
- Department of Radiology and Nuclear Medicine, University Medical Center Rotterdam, Erasmus MC, 3015 GD Rotterdam, The Netherlands; (E.M.); (E.S.); (S.B.); (L.v.d.B.); (M.H.); (D.S.); (C.d.R.); (S.U.D.)
- Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands
| | - Yann Seimbille
- Department of Radiology and Nuclear Medicine, University Medical Center Rotterdam, Erasmus MC, 3015 GD Rotterdam, The Netherlands; (E.M.); (E.S.); (S.B.); (L.v.d.B.); (M.H.); (D.S.); (C.d.R.); (S.U.D.)
- Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands
- TRIUMF, Life Sciences Division, Vancouver, BC V6T 2A3, Canada
| |
Collapse
|
3
|
Lahnif H, Grus T, Salvanou EA, Deligianni E, Stellas D, Bouziotis P, Rösch F. Old Drug, New Delivery Strategy: MMAE Repackaged. Int J Mol Sci 2023; 24:ijms24108543. [PMID: 37239890 DOI: 10.3390/ijms24108543] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2023] [Revised: 05/04/2023] [Accepted: 05/07/2023] [Indexed: 05/28/2023] Open
Abstract
Targeting therapy is a concept that has gained significant importance in recent years, especially in oncology. The severe dose-limiting side effects of chemotherapy necessitate the development of novel, efficient and tolerable therapy approaches. In this regard, the prostate specific membrane antigene (PSMA) has been well established as a molecular target for diagnosis of, as well as therapy for, prostate cancer. Although most PSMA-targeting ligands are radiopharmaceuticals used in imaging or radioligand therapy, this article evaluates a PSMA-targeting small molecule-drug conjugate, and, thus, addresses a hitherto little-explored field. PSMA binding affinity and cytotoxicity were determined in vitro using cell-based assays. Enzyme-specific cleavage of the active drug was quantified via an enzyme-based assay. Efficacy and tolerability in vivo were assessed using an LNCaP xenograft model. Histopathological characterization of the tumor in terms of apoptotic status and proliferation rate was carried out using caspase-3 and Ki67 staining. The binding affinity of the Monomethyl auristatin E (MMAE) conjugate was moderate, compared to the drug-free PSMA ligand. Cytotoxicity in vitro was in the nanomolar range. Both binding and cytotoxicity were found to be PSMA-specific. Additionally, complete MMAE release could be reached after incubation with cathepsin B. In vivo, the MMAE conjugate displayed good tolerability and dose-dependent inhibition of tumor growth. Immunohistochemical and histological studies revealed the antitumor effect of MMAE.VC.SA.617, resulting in the inhibition of proliferation and the enhancement of apoptosis. The developed MMAE conjugate showed good properties in vitro, as well as in vivo, and should, therefore, be considered a promising candidate for a translational approach.
Collapse
Affiliation(s)
- Hanane Lahnif
- Department of Chemistry-TRIGA Site, Johannes Gutenberg University Mainz, 55128 Mainz, Germany
| | - Tilmann Grus
- Department of Chemistry-TRIGA Site, Johannes Gutenberg University Mainz, 55128 Mainz, Germany
| | - Evangelia-Alexandra Salvanou
- Radiochemical Studies Laboratory, INRASTES, National Center for Scientific Research "Demokritos", Ag. Paraskevi, 15341 Athens, Greece
| | - Elisavet Deligianni
- Institute of Chemical Biology, National Hellenic Research Foundation, 11635 Athens, Greece
| | - Dimitris Stellas
- Institute of Chemical Biology, National Hellenic Research Foundation, 11635 Athens, Greece
| | - Penelope Bouziotis
- Radiochemical Studies Laboratory, INRASTES, National Center for Scientific Research "Demokritos", Ag. Paraskevi, 15341 Athens, Greece
| | - Frank Rösch
- Department of Chemistry-TRIGA Site, Johannes Gutenberg University Mainz, 55128 Mainz, Germany
| |
Collapse
|
4
|
Bernal L, Pinzi L, Rastelli G. Identification of Promising Drug Candidates against Prostate Cancer through Computationally-Driven Drug Repurposing. Int J Mol Sci 2023; 24:ijms24043135. [PMID: 36834548 PMCID: PMC9964599 DOI: 10.3390/ijms24043135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2022] [Revised: 02/02/2023] [Accepted: 02/03/2023] [Indexed: 02/08/2023] Open
Abstract
Prostate cancer (PC) is one of the most common types of cancer in males. Although early stages of PC are generally associated with favorable outcomes, advanced phases of the disease present a significantly poorer prognosis. Moreover, currently available therapeutic options for the treatment of PC are still limited, being mainly focused on androgen deprivation therapies and being characterized by low efficacy in patients. As a consequence, there is a pressing need to identify alternative and more effective therapeutics. In this study, we performed large-scale 2D and 3D similarity analyses between compounds reported in the DrugBank database and ChEMBL molecules with reported anti-proliferative activity on various PC cell lines. The analyses included also the identification of biological targets of ligands with potent activity on PC cells, as well as investigations on the activity annotations and clinical data associated with the more relevant compounds emerging from the ligand-based similarity results. The results led to the prioritization of a set of drugs and/or clinically tested candidates potentially useful in drug repurposing against PC.
Collapse
Affiliation(s)
- Leonardo Bernal
- Department of Life Sciences, University of Modena and Reggio Emilia, Via Giuseppe Campi 103, 41125 Modena, Italy
- Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, 41125 Modena, Italy
| | - Luca Pinzi
- Department of Life Sciences, University of Modena and Reggio Emilia, Via Giuseppe Campi 103, 41125 Modena, Italy
| | - Giulio Rastelli
- Department of Life Sciences, University of Modena and Reggio Emilia, Via Giuseppe Campi 103, 41125 Modena, Italy
- Correspondence: ; Tel.: +39-059-2058564
| |
Collapse
|
5
|
Functionalization of Nanosystems in Cancer Treatment. Cancer Nanotechnol 2023. [DOI: 10.1007/978-3-031-17831-3_3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
|
6
|
Krishnan MA, Pandit A, Sharma R, Chelvam V. Imaging of prostate cancer: optimizing affinity to prostate specific membrane antigen by spacer modifications in a tumor spheroid model. J Biomol Struct Dyn 2022; 40:9909-9930. [PMID: 34180367 DOI: 10.1080/07391102.2021.1936642] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Early diagnosis of prostate cancer (PCa) is crucial for staging, treatment and management of patients. Prostate specific membrane antigen (PSMA), highly over-expressed on PCa cells, is an excellent target for selective imaging of PCa. In recent years, various scaffolds have been explored as potential carriers to target diagnostic and therapeutic agents to PSMA+ tumour cells. Numerous fluorescent or radioisotope probes linked via a peptide linker have been developed that selectively binds to PCa cells. However, there are very few reports that examine the effects of chemical modifications in the peptide linker of an imaging probe on its affinity to PSMA protein. This report systematically investigates the impact of hydrophobic aromatic moieties in the peptide linker on PSMA affinity and in vitro performance. For this, a series of fluorescent bioconjugates 12-17 with different aromatic spacers were designed, synthesized, and their interactions within the PSMA pocket were first analysed in silico. Cell uptake studies were then performed for 12-17 in PSMA+ cell lines and 3D tumour models in vitro. Binding affinity values of 12-17 were found to be in the range of 36 to 157.9 nM, and 12 with three aromatic groups in the spacer exhibit highest affinity (KD = 36 nM) compared to 17 which is devoid of aromatic groups. These studies suggest that aromatic groups in the spacer region can significantly affect deep tissue imaging of fluorescent bioconjugates. Bioconjugate 12 can be a promising diagnostic tool, and conjugation to near-infrared agents would further its applications in deep-tissue imaging and surgery. Communicated by Ramaswamy H. Sarma.
Collapse
Affiliation(s)
- Mena Asha Krishnan
- Department of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Indore, India
| | - Amit Pandit
- Department of Chemistry, Indian Institute of Technology Indore, Indore, India
| | - Rajesh Sharma
- School of Pharmacy, Devi Ahilya University, Indore, India
| | - Venkatesh Chelvam
- Department of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Indore, India.,Department of Chemistry, Indian Institute of Technology Indore, Indore, India
| |
Collapse
|
7
|
Wang L, Tang L, Liu Y, Wu H, Liu Z, Li J, Pan Y, Akkaya EU. Prostate-specific membrane antigen (PSMA) targeted singlet oxygen delivery via endoperoxide tethered ligands. Chem Commun (Camb) 2022; 58:1902-1905. [PMID: 35029263 DOI: 10.1039/d1cc05810j] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Singlet oxygen is the primary agent responsible for the therapeutic effects of photodynamic therapy (PDT). In this work, we demonstrate that singlet oxygen release due to thermal endoperoxide cycloreversion can be targeted towards specific features of selected cancer cells, and this targeted singlet oxygen delivery can serve as an effective therapeutic tool. Thus, cytotoxic singlet oxygen can be delivered regioselectively into prostate specific membrane antigen (PSMA) overexpressing lymph node carcinoma (LNCaP) cells. However, unlike typical photodynamic processes, there is no need for light or oxygen. The potential of the approach is exciting, considering the limitations on the availability of light and oxygen in deep-seated tumors.
Collapse
Affiliation(s)
- Lei Wang
- State Key Laboratory of Fine Chemicals, Department of Pharmaceutical Science, Dalian University of Technology, 2 Linggong Road, Dalian, Liaoning, 116024, China.
| | - Lei Tang
- State Key Laboratory of Fine Chemicals, Department of Pharmaceutical Science, Dalian University of Technology, 2 Linggong Road, Dalian, Liaoning, 116024, China.
| | - Yingjie Liu
- State Key Laboratory of Fine Chemicals, Department of Pharmaceutical Science, Dalian University of Technology, 2 Linggong Road, Dalian, Liaoning, 116024, China.
| | - Hao Wu
- State Key Laboratory of Fine Chemicals, Department of Pharmaceutical Science, Dalian University of Technology, 2 Linggong Road, Dalian, Liaoning, 116024, China.
| | - Ziang Liu
- State Key Laboratory of Fine Chemicals, Department of Pharmaceutical Science, Dalian University of Technology, 2 Linggong Road, Dalian, Liaoning, 116024, China.
| | - Jin Li
- State Key Laboratory of Fine Chemicals, Department of Pharmaceutical Science, Dalian University of Technology, 2 Linggong Road, Dalian, Liaoning, 116024, China.
| | - Yue Pan
- State Key Laboratory of Fine Chemicals, Department of Pharmaceutical Science, Dalian University of Technology, 2 Linggong Road, Dalian, Liaoning, 116024, China.
| | - Engin U Akkaya
- State Key Laboratory of Fine Chemicals, Department of Pharmaceutical Science, Dalian University of Technology, 2 Linggong Road, Dalian, Liaoning, 116024, China.
| |
Collapse
|
8
|
Cushman M. Design and Synthesis of Indenoisoquinolines Targeting Topoisomerase I and Other Biological Macromolecules for Cancer Chemotherapy. J Med Chem 2021; 64:17572-17600. [PMID: 34879200 DOI: 10.1021/acs.jmedchem.1c01491] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The discovery that certain indenoisoquinolines inhibit the religation reaction of DNA in the topoisomerase I-DNA-indenoisoquinoline ternary complex led to a structure-based drug design research program which resulted in three representatives that entered Phase I clinical trials in cancer patients at the National Cancer Institute. This has stimulated a great deal of interest in the design and execution of new synthetic pathways for indenoisoquinoline production. More recently, modulation of the substitution pattern and chemical nature of substituents on the indenoisoquinoline scaffold has resulted in a widening scope of additional biological targets, including RXR, PARP-1, MYC promoter G-quadruplex, topoisomerase II, estrogen receptor, VEGFR-2, HIF-1α, and tyrosyl DNA phosphodiesterases 1 and 2. Furthermore, convincing evidence has been advanced supporting the potential use of indenoisoquinolines for the treatment of diseases other than cancer. The rapidly expanding indenoisoquinoline knowledge base has provided a firm foundation for further advancements in indenoisoquinoline chemistry, pharmacology, and therapeutics.
Collapse
Affiliation(s)
- Mark Cushman
- Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907, United States
| |
Collapse
|
9
|
Guo XX, Guo ZH, Lu JS, Xie WS, Zhong QZ, Sun XD, Wang XM, Wang JY, Liu M, Zhao LY. All-purpose nanostrategy based on dose deposition enhancement, cell cycle arrest, DNA damage, and ROS production as prostate cancer radiosensitizer for potential clinical translation. NANOSCALE 2021; 13:14525-14537. [PMID: 34473816 DOI: 10.1039/d1nr03869a] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
Radiotherapy (RT) is one of the main treatments for men with prostate cancer (PCa). To date, numerous sophisticated nano-formulations as radiosensitizers have been synthesized with inspiring therapeutic effects both in vitro and in vivo; however, almost all the attention has been paid on the enhanced dose deposition effect by secondary electrons of nanomaterials with high atomic numbers (Z); despite this, cell-cycle arrest, DNA damage, and also reactive oxygen species (ROS) production are critical working mechanisms that account for radiosensitization. Herein, an 'all-purpose' nanostrategy based on dose deposition enhancement, cell cycle arrest, and ROS production as prostate cancer radiosensitizer for potential clinical translation was proposed. The rather simple structure of docetaxel-loaded Au nanoparticles (NPs) with prostate specific membrane antigen (PSMA) ligand conjugation have been successfully synthesized. Enhanced cellular uptake achieved via the selective internalization of the NPs by PCa cells with positive PSMA expression could guarantee enhanced dose deposition. Moreover, the as-synthesized nanosystem could effectively arrest the cell cycle at G2/M phases, which would reduce the ability of DNA damage repair for more irradiation sensitive of the PCa cells. Moreover, the G2/M phase arrest would further promote cascade retention and the enrichment of NPs within the cells. Furthermore, ROS generation and double strand breaks greatly promoted by NPs under irradiation (IR) could also provide an underlying basis for effective radiosensitizers. In vitro and in vivo investigations confirmed the as-synthesized NPs as an effective nano-radiosensitizer with ideal safety. More importantly, all moieties within the present nanosystem have been approved by FDA for the purpose of PCa treatment, thus making it highly attractive for clinical translation.
Collapse
Affiliation(s)
- Xiao-Xiao Guo
- Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, 100730, China
- Graduate School of Peking Union Medical College, Beijing, 100730, China
| | - Zhen-Hu Guo
- Key Laboratory of Advanced Materials, Ministry of Education of China, School of Materials Science and Engineering, Tsinghua University, Beijing, 100084, China
| | - Jing-Song Lu
- Key Laboratory of Advanced Materials, Ministry of Education of China, School of Materials Science and Engineering, Tsinghua University, Beijing, 100084, China
| | - Wen-Sheng Xie
- Key Laboratory of Advanced Materials, Ministry of Education of China, School of Materials Science and Engineering, Tsinghua University, Beijing, 100084, China
| | - Qiu-Zi Zhong
- Department of Radiotherapy, National Center of Gerontology, Institute of Geriatric Medicine, Beijing Hospital, Chinese Academy of Medical Science, Beijing, 100730, China
| | - Xiao-Dan Sun
- Key Laboratory of Advanced Materials, Ministry of Education of China, School of Materials Science and Engineering, Tsinghua University, Beijing, 100084, China
| | - Xiu-Mei Wang
- Key Laboratory of Advanced Materials, Ministry of Education of China, School of Materials Science and Engineering, Tsinghua University, Beijing, 100084, China
| | - Jian-Ye Wang
- Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, 100730, China
| | - Ming Liu
- Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, 100730, China
| | - Ling-Yun Zhao
- Key Laboratory of Advanced Materials, Ministry of Education of China, School of Materials Science and Engineering, Tsinghua University, Beijing, 100084, China
| |
Collapse
|
10
|
Cohen L, Livney YD, Assaraf YG. Targeted nanomedicine modalities for prostate cancer treatment. Drug Resist Updat 2021; 56:100762. [PMID: 33857756 DOI: 10.1016/j.drup.2021.100762] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2021] [Revised: 03/16/2021] [Accepted: 03/18/2021] [Indexed: 12/17/2022]
Abstract
Prostate cancer (PC) is the second most common cause of death amongst men in the USA. Therapy of PC has been transformed in the past decade by introducing novel therapeutics, advanced functional imaging and diagnostic approaches, next generation sequencing, as well as improved application of existing therapies in localized PC. Treatment of PC at the different stages of the disease may include surgery, androgen deprivation therapy (ADT), chemotherapy and radiation therapy. However, although ADT has proven efficacious in PC treatment, its effectiveness may be temporary, as these tumors frequently develop molecular mechanisms of therapy resistance, which allow them to survive and proliferate even under conditions of testosterone deprivation, inhibition of androgen receptor signaling, or cytotoxic drug treatment. Importantly, ADT was found to induce key alterations which frequently result in the formation of metastatic tumors displaying a therapy refractory phenotype. Hence, to overcome these serious therapeutic impediments, novel PC cell-targeted therapeutic strategies are being developed. These include diverse platforms enabling specific enhanced antitumor drug uptake and increased intracellular accumulation. Studies have shown that these novel treatment modalities lead to enhanced antitumor activity and diminished systemic toxicity due to the use of selective targeting and decreased drug doses. The underlying mechanism of targeting and internalization is based upon the interaction between a selective ligand, conjugated to a drug-loaded nanoparticle or directly to an anti-cancer drug, and a specific plasma membrane biomarker, uniquely overexpressed on the surface of PC cells. Another targeted therapeutic approach is the delivery of unique anti-oncogenic signaling pathway-based therapeutic drugs, which are selectively cytotoxic to PC cells. The current paper reviews PC targeted modalities reported in the past 6 years, and discusses both the advantages and limitations of the various targeted treatment strategies.
Collapse
Affiliation(s)
- Lital Cohen
- The Laboratory of Biopolymers for Food and Health, Department of Biotechnology and Food Engineering, Technion - Israel Institute of Technology, Haifa, 3200003, Israel
| | - Yoav D Livney
- The Laboratory of Biopolymers for Food and Health, Department of Biotechnology and Food Engineering, Technion - Israel Institute of Technology, Haifa, 3200003, Israel.
| | - Yehuda G Assaraf
- The Fred Wyszkowski Cancer Research Laboratory, Department of Biology, Technion - Israel Institute of Technology, Haifa, 3200003, Israel.
| |
Collapse
|
11
|
Asha Krishnan M, Yadav K, Roach P, Chelvam V. A targeted near-infrared nanoprobe for deep-tissue penetration and imaging of prostate cancer. Biomater Sci 2021; 9:2295-2312. [PMID: 33554988 DOI: 10.1039/d0bm01970d] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
The current challenge in fluorescence guided surgery (FGS) for prostate cancer (PCa) is in the design of imaging probes with high selectivity, clear visualization of tumour margins, and minimal toxicity. This report aims to design and develop a novel NIR-nanoprobe, and evaluate its potential in the penetration of PCa tumour tissues. The PSMA receptor-targeted quantum dot (PSMA-QD655) is a NIR, deep-tissue imaging agent, which has the potential for intraoperative navigation during surgery and improved detection specificity for PCa. The probe was designed and synthesized by conjugating functionalized amino-PEG quantum dots (QDs) through a heterobifunctional linker to a DUPA targeted polypeptide construct. The nanoprobe was evaluated in vitro in PSMA+ PCa cell lines for specificity and its binding affinity was determined by flow cytometric analysis. The penetration efficacy was tested further on large PCa 3D tumour spheroids (dia ∼1200 μm, thickness ∼450 μm) by deep tissue multiphoton imaging. PSMA-QD655 was found to be an efficient deep tissue intra-operative guided surgical tool with a high affinity (KD = 15.3 nM) and penetrative capacity. The results have been demonstrated in vitro in 2D and 3D tissue models, mimicking cancer lesions in vivo. In summary, we have developed a deep-tissue imaging NIR nanoprobe targeting prostatic lesions that (i) binds to PSMA+ tumour with sub-nanomolar affinity and high specificity, (ii) shows an excellent safety profile in primary cell lines in vitro and (iii) shows high penetrative capacity in a 3D prostate tumour model (∼450 μm tissue depth).
Collapse
Affiliation(s)
- Mena Asha Krishnan
- Department of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Indore 453 552, India.
| | | | | | | |
Collapse
|
12
|
Small Molecule-Based Prodrug Targeting Prostate Specific Membrane Antigen for the Treatment of Prostate Cancer. Cancers (Basel) 2021; 13:cancers13030417. [PMID: 33499427 PMCID: PMC7865627 DOI: 10.3390/cancers13030417] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2020] [Revised: 01/18/2021] [Accepted: 01/19/2021] [Indexed: 11/16/2022] Open
Abstract
Metastatic castration-resistant prostate cancer poses a serious clinical problem with poor outcomes and remains a deadly disease. New targeted treatment options are urgently needed. PSMA is highly expressed in prostate cancer and has been an attractive biomarker for the treatment of prostate cancer. In this study, we explored the feasibility of targeted delivery of an antimitotic drug, monomethyl auristatin E (MMAE), to tumor tissue using a small-molecule based PSMA lig-and. With the aid of Cy5.5, we found that a cleavable linker is vital for the antitumor activity of the ligand-drug conjugate and have developed a new PSMA-targeting prodrug, PSMA-1-VcMMAE. In in vitro studies, PSMA-1-VcMMAE was 48-fold more potent in killing PSMA-positive PC3pip cells than killing PSMA-negative PC3flu cells. In in vivo studies, PSMA-1-VcMMAE significantly inhibited tumor growth leading to prolonged animal survival in different animal models, including metastatic prostate cancer models. Compared to anti-PSMA antibody-MMAE conjugate (PSMA-ADC) and MMAE, PSMA-1-VcMMAE had over a 10-fold improved maximum tolerated dose, resulting in improved therapeutic index. The small molecule-drug conjugates reported here can be easily synthesized and are more cost efficient than anti-body-drug conjugates. The therapeutic profile of the PSMA-1-VcMMAE encourages further clin-ical development for the treatment of advanced prostate cancer.
Collapse
|
13
|
Enzyme-responsive polymeric micelles of cabazitaxel for prostate cancer targeted therapy. Acta Biomater 2020; 113:501-511. [PMID: 32562805 DOI: 10.1016/j.actbio.2020.06.019] [Citation(s) in RCA: 61] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2020] [Revised: 06/10/2020] [Accepted: 06/11/2020] [Indexed: 12/31/2022]
Abstract
Cabazitaxel, a novel tubulin inhibitor with poor affinity for P-glycoprotein, is a second-generation taxane holding great promise for the treatment of metastatic castration-resistant prostate cancer. However, its poor solubility and lack of target-ability limit its therapeutic applications. Herein, we develop a biodegradable, enzyme-responsive, and targeted polymeric micelle for cabazitaxel. The micelle is formed from two amphiphilic block copolymers. The first block copolymer consists of PEG, an enzyme-responsive peptide, and cholesterol; whereas the second block copolymer consists of a targeting ligand, PEG and cholesterol. The enzyme-responsive peptide is cleavable in the presence of matrixmetaloproteinase-2 (MMP-2), which is overexpressed in the tumor microenvironment of prostate cancer. The micelle showed a very low critical micelle concentration (CMC), high drug loading, and high entrapment efficiency. Release of cabazitaxel from the micelle is dependent on the cleavage of the enzyme-responsive peptide. Moreover, the micelle showed dramatically higher cellular uptake in prostate cancer cells compared to free cabazitaxel. Importantly, the ligand-coupled polymeric micelle demonstrated better inhibition of tumor growth in mice bearing prostate cancer xenografts compared to unmodified micelle and free cabazitaxel. Taken together, these findings suggest that the enzyme-responsive cabazitaxel micelle is a potent and promising drug delivery system for advanced prostate cancer therapy. STATEMENT OF SIGNIFICANCE: Herein, we develop a biodegradable, enzyme-responsive, and actively targeted polymer micelle for cabazitaxel, which is a novel tubulin inhibitor with poor affinity for P-glycoprotein. Despite cabazitaxel's great promise for metastatic castration-resistant prostate cancer, its poor solubility, lack of target-ability, and high systemic toxicity limit its therapeutic applications, and therefore a targeted delivery system is highly needed for cabazitaxel. Our results demonstrate the importance of active targeting in targeted prostate cancer therapy. Encapsulating cabazitaxel in the micelle increases its activity and is expected to reduce its systemic toxicity, which is a major hurdle in its clinical applications. Moreover, the polymeric micelle may servers as a promising nanoscale platform for the targeted delivery of other chemotherapeutic agents to prostate cancer.
Collapse
|
14
|
Zhou Y, Mowlazadeh Haghighi S, Liu Z, Wang L, Hruby VJ, Cai M. Development of Ligand-Drug Conjugates Targeting Melanoma through the Overexpressed Melanocortin 1 Receptor. ACS Pharmacol Transl Sci 2020; 3:921-930. [PMID: 33073191 DOI: 10.1021/acsptsci.0c00072] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2020] [Indexed: 12/31/2022]
Abstract
Melanoma is a lethal form of skin cancer. Despite recent breakthroughs of BRAF-V600E and PD-1 inhibitors showing remarkable clinical responses, melanoma can eventually survive these targeted therapies and become resistant. To solve the drug resistance issue, we designed and synthesized ligand-drug conjugates that couple cytotoxic drugs, which have a low cancer resistance issue, with the melanocortin 1 receptor (MC1R) agonist melanotan-II (MT-II), which provides specificity to MC1R-overexpressing melanoma. The drug-MT-II conjugates maintain strong binding interactions to MC1R and induce selective drug delivery to A375 melanoma cells through its MT-II moiety in vitro. Furthermore, using camptothecin as the cytotoxic drug, camptothecin-MT-II (compound 1) can effectively inhibit A375 melanoma cell growth with an IC50 of 16 nM. By providing selectivity to melanoma cells through its MT-II moiety, this approach of drug-MT-II conjugates enables us to have many more options for cytotoxic drug selection, which can be the key to solving the cancer resistant problem for melanoma.
Collapse
Affiliation(s)
- Yang Zhou
- Department of Chemistry and Biochemistry, The University of Arizona, Tucson, Arizona 85721, United States
| | - Saghar Mowlazadeh Haghighi
- Department of Chemistry and Biochemistry, The University of Arizona, Tucson, Arizona 85721, United States
| | - Zekun Liu
- Department of Chemistry and Biochemistry, The University of Arizona, Tucson, Arizona 85721, United States
| | - Lingzhi Wang
- Department of Chemistry and Biochemistry, The University of Arizona, Tucson, Arizona 85721, United States
| | - Victor J Hruby
- Department of Chemistry and Biochemistry, The University of Arizona, Tucson, Arizona 85721, United States
| | - Minying Cai
- Department of Chemistry and Biochemistry, The University of Arizona, Tucson, Arizona 85721, United States
| |
Collapse
|
15
|
Roy J, Hettiarachchi SU, Kaake M, Mukkamala R, Low PS. Design and validation of fibroblast activation protein alpha targeted imaging and therapeutic agents. Theranostics 2020; 10:5778-5789. [PMID: 32483418 PMCID: PMC7254991 DOI: 10.7150/thno.41409] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2019] [Accepted: 04/03/2020] [Indexed: 12/21/2022] Open
Abstract
Background: Cancer-associated fibroblasts (CAFs) comprise a major cell type in the tumor microenvironment where they support tumor growth and survival by producing extracellular matrix, secreting immunosuppressive cytokines, releasing growth factors, and facilitating metastases. Because tumors with elevated CAFs are characterized by poorer prognosis, considerable effort is focused on developing methods to quantitate, suppress and/or eliminate CAFs. We exploit the elevated expression of fibroblast activation protein (FAP) on CAFs to target imaging and therapeutic agents selectively to these fibroblasts in solid tumors. Methods: FAP-targeted optical imaging, radioimaging, and chemotherapeutic agents were synthesized by conjugating FAP ligand (FL) to either a fluorescent dye, technetium-99m, or tubulysin B hydrazide. In vitro and in vivo studies were performed to determine the specificity and selectivity of each conjugate for FAP in vitro and in vivo. Results: FAP-targeted imaging and therapeutic conjugates showed high binding specificity and affinity in the low nanomolar range. Injection of FAP-targeted 99mTc into tumor-bearing mice enabled facile detection of tumor xenografts with little off-target uptake. Optical imaging of malignant lesions was also readily achieved following intravenous injection of FAP-targeted near-infrared fluorescent dye. Finally, systemic administration of a tubulysin B conjugate of FL promoted complete eradication of solid tumors with no evidence of gross toxicity to the animals. Conclusion: In view of the near absence of FAP on healthy cells, we conclude that targeting of FAP on cancer-associated fibroblasts can enable highly specific imaging and therapy of solid tumors.
Collapse
Affiliation(s)
| | | | | | | | - Philip S Low
- Department of Chemistry and Institute for Drug Discovery, Purdue University, West Lafayette, Indiana 47907, United States
| |
Collapse
|
16
|
Glyco-nanoparticles: New drug delivery systems in cancer therapy. Semin Cancer Biol 2019; 69:24-42. [PMID: 31870939 DOI: 10.1016/j.semcancer.2019.12.004] [Citation(s) in RCA: 32] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2019] [Revised: 11/28/2019] [Accepted: 12/02/2019] [Indexed: 12/24/2022]
Abstract
Cancer is known as one of the most common diseases that are associated with high mobility and mortality in the world. Despite several efforts, current cancer treatment modalities often are highly toxic and lack efficacy and specificity. However, the application of nanotechnology has led to the development of effective nanosized drug delivery systems which are highly selective for tumors and allow a slow release of active anticancer agents. Different Nanoparticles (NPs) such as the silicon-based nano-materials, polymers, liposomes and metal NPs have been designed to deliver anti-cancer drugs to tumor sites. Among different drug delivery systems, carbohydrate-functionalized nanomaterials, specially based on their multi-valent binding capacities and desirable bio-compatibility, have attracted considerable attention as an excellent candidate for controlled release of therapeutic agents. In addition, these carbohydrate functionalized nano-carriers are more compatible with construction of the intracellular delivery platforms like the carbohydrate-modified metal NPs, quantum dots, and magnetic nano-materials. In this review, we discuss recent research in the field of multifunctional glycol-nanoparticles (GNPs) intended for cancer drug delivery applications.
Collapse
|
17
|
Beekman AM, Cominetti MMD, Cartwright OC, Boger DL, Searcey M. A small molecule drug conjugate (SMDC) of DUPA and a duocarmycin built on the solid phase. MEDCHEMCOMM 2019; 10:2170-2174. [PMID: 32879717 DOI: 10.1039/c9md00279k] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/15/2019] [Accepted: 11/12/2019] [Indexed: 01/02/2023]
Abstract
In a proof-of-concept study, solid phase synthesis allowed the rapid generation of a small molecule drug conjugate in which the glutamate carboxypeptidase II (GCPII) targeting small molecule DUPA was conjugated to the alkylating subunit of the potent cytotoxin duocarmycin SA. The targeted SMDC contained a cathepsin B cleavable linker, which was shown to be active and selective against cathepsin B over-expressing and GCPII-expressing tumour cell lines.
Collapse
Affiliation(s)
- Andrew Michael Beekman
- School of Pharmacy & School of Chemistry , University of East Anglia , Norwich Research Park, Norwich , Norfolk , NR47TJ , UK . ;
| | - Marco M D Cominetti
- School of Pharmacy & School of Chemistry , University of East Anglia , Norwich Research Park, Norwich , Norfolk , NR47TJ , UK . ;
| | - Oliver Charles Cartwright
- School of Pharmacy & School of Chemistry , University of East Anglia , Norwich Research Park, Norwich , Norfolk , NR47TJ , UK . ;
| | - Dale L Boger
- Department of Chemistry , The Scripps Research Institute , La Jolla , California 92037 , USA
| | - Mark Searcey
- School of Pharmacy & School of Chemistry , University of East Anglia , Norwich Research Park, Norwich , Norfolk , NR47TJ , UK . ;
| |
Collapse
|
18
|
Tumor Uptake of Triazine Dendrimers Decorated with Four, Sixteen, and Sixty-Four PSMA-Targeted Ligands: Passive versus Active Tumor Targeting. Biomolecules 2019; 9:biom9090421. [PMID: 31466360 PMCID: PMC6770530 DOI: 10.3390/biom9090421] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2019] [Revised: 08/13/2019] [Accepted: 08/16/2019] [Indexed: 12/20/2022] Open
Abstract
Various glutamate urea ligands have displayed high affinities to prostate specific membrane antigen (PSMA), which is highly overexpressed in prostate and other cancer sites. The multivalent versions of small PSMA-targeted molecules are known to be even more efficiently bound to the receptor. Here, we employ a well-known urea-based ligand, 2-[3-(1,3-dicarboxypropyl)-ureido] pentanedioic acid (DUPA) and triazine dendrimers in order to study the effect of molecular size on multivalent targeting in prostate cancer. The synthetic route starts with the preparation of a dichlorotriazine bearing DUPA in 67% overall yield over five steps. This dichlorotriazine reacts with G1, G3, and G5 triazine dendrimers bearing a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) group for 64Cu-labeling at the core to afford poly(monochlorotriazine) intermediates. Addition of 4-aminomethylpiperidine (4-AMP) and the following deprotection produce the target compounds, G1-(DUPA)4, G3-(DUPA)16, and G5-(DUPA)64. These targets include 4/16/64 DUPA groups on the surface and a DOTA group at the core, respectively. In vitro cell assay using PC3-PIP (PSMA positive) and PC3-FLU (PSMA negative) cells reveals that G1-(DUPA)4 has the highest PC3-PIP to PC3-FLU uptake ratio (10-fold) through the PSMA-mediated specific uptake. While G5-(DUPA)64 displayed approximately 12 times higher binding affinity (IC50 23.6 nM) to PC3-PIP cells than G1-(DUPA)4 (IC50 282.3 nM) as evaluated in a competitive binding assay, the G5 dendrimer also showed high non-specific binding to PC3-FLU cells. In vivo uptake of the 64Cu-labeled dendrimers was also evaluated in severe combined inmmunodeficient (SCID) mice bearing PC3-PIP and PC3-FLU xenografts on each shoulder, respectively. Interestingly, quantitative imaging analysis of positron emission tomograph (PET) displayed the lowest tumor uptake in PC3-PIP cells for the midsize dendrimer G3-(DUPA)16 (19.4 kDa) (0.66 ± 0.15%ID/g at 1 h. p.i., 0.64 ± 0.11%ID/g at 4 h. p.i., and 0.67 ± 0.08%ID/g at 24 h. p.i.). Through the specific binding of G1-(DUPA)4 to PSMA, the smallest dendrimer (5.1 kDa) demonstrated the highest PC3-PIP to muscle and PC3-PIP to PC3-FLU uptake ratios (17.7 ± 5.5 and 6.7 ± 3.0 at 4 h p.i., respectively). In addition, the enhanced permeability and retention (EPR) effect appeared to be an overwhelming factor for tumor uptake of the largest dendrimer G5-(DUPA)64 as the uptake was at a similar level irrelevant to the PSMA expression.
Collapse
|
19
|
Synthesis and biological evaluation of PSMA-targeting paclitaxel conjugates. Bioorg Med Chem Lett 2019; 29:2229-2235. [DOI: 10.1016/j.bmcl.2019.06.035] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2019] [Revised: 06/17/2019] [Accepted: 06/19/2019] [Indexed: 12/17/2022]
|
20
|
Leamon CP, Reddy JA, Bloomfield A, Dorton R, Nelson M, Vetzel M, Kleindl P, Hahn S, Wang K, Vlahov IR. Prostate-Specific Membrane Antigen-Specific Antitumor Activity of a Self-Immolative Tubulysin Conjugate. Bioconjug Chem 2019; 30:1805-1813. [PMID: 31075200 DOI: 10.1021/acs.bioconjchem.9b00335] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- Christopher P. Leamon
- Endocyte, Inc., 3000 Kent Avenue, Suite A1-100, West Lafayette, Indiana 47906, United States
| | - Joseph A. Reddy
- Endocyte, Inc., 3000 Kent Avenue, Suite A1-100, West Lafayette, Indiana 47906, United States
| | - Alicia Bloomfield
- Endocyte, Inc., 3000 Kent Avenue, Suite A1-100, West Lafayette, Indiana 47906, United States
| | - Ryan Dorton
- Endocyte, Inc., 3000 Kent Avenue, Suite A1-100, West Lafayette, Indiana 47906, United States
| | - Melissa Nelson
- Endocyte, Inc., 3000 Kent Avenue, Suite A1-100, West Lafayette, Indiana 47906, United States
| | - Marilynn Vetzel
- Endocyte, Inc., 3000 Kent Avenue, Suite A1-100, West Lafayette, Indiana 47906, United States
| | - Paul Kleindl
- Endocyte, Inc., 3000 Kent Avenue, Suite A1-100, West Lafayette, Indiana 47906, United States
| | - Spencer Hahn
- Endocyte, Inc., 3000 Kent Avenue, Suite A1-100, West Lafayette, Indiana 47906, United States
| | - Kevin Wang
- Endocyte, Inc., 3000 Kent Avenue, Suite A1-100, West Lafayette, Indiana 47906, United States
| | - Iontcho R. Vlahov
- Endocyte, Inc., 3000 Kent Avenue, Suite A1-100, West Lafayette, Indiana 47906, United States
| |
Collapse
|
21
|
Ivanenkov YA, Machulkin AE, Garanina AS, Skvortsov DA, Uspenskaya AA, Deyneka EV, Trofimenko AV, Beloglazkina EK, Zyk NV, Koteliansky VE, Bezrukov DS, Aladinskaya AV, Vorobyeva NS, Puchinina MM, Riabykh GK, Sofronova AA, Malyshev AS, Majouga AG. Synthesis and biological evaluation of Doxorubicin-containing conjugate targeting PSMA. Bioorg Med Chem Lett 2019; 29:1246-1255. [DOI: 10.1016/j.bmcl.2019.01.040] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2018] [Revised: 01/15/2019] [Accepted: 01/30/2019] [Indexed: 12/19/2022]
|
22
|
Raposo Moreira Dias A, Pina A, Dean A, Lerchen H, Caruso M, Gasparri F, Fraietta I, Troiani S, Arosio D, Belvisi L, Pignataro L, Dal Corso A, Gennari C. Neutrophil Elastase Promotes Linker Cleavage and Paclitaxel Release from an Integrin-Targeted Conjugate. Chemistry 2019; 25:1696-1700. [PMID: 30452790 PMCID: PMC6471013 DOI: 10.1002/chem.201805447] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2018] [Revised: 11/16/2018] [Indexed: 12/16/2022]
Abstract
This work takes advantage of one of the hallmarks of cancer, that is, the presence of tumor infiltrating cells of the immune system and leukocyte-secreted enzymes, to promote the activation of an anticancer drug at the tumor site. The peptidomimetic integrin ligand cyclo(DKP-RGD) was found to accumulate on the surface of αv β3 integrin-expressing human renal cell carcinoma 786-O cells. The ligand was conjugated to the anticancer drug paclitaxel through a Asn-Pro-Val (NPV) tripeptide linker, which is a substrate of neutrophil-secreted elastase. In vitro linker cleavage assays and cell antiproliferative experiments demonstrate the efficacy of this tumor-targeting conjugate, opening the way to potential therapeutic applications.
Collapse
Affiliation(s)
| | - Arianna Pina
- Università degli Studi di MilanoDipartimento di ChimicaVia C. Golgi, 19I-20133MilanItaly
| | - Amelia Dean
- Università degli Studi di MilanoDipartimento di ChimicaVia C. Golgi, 19I-20133MilanItaly
| | | | - Michele Caruso
- Nerviano Medical SciencesViale Pasteur, 10I-20014NervianoItaly
| | - Fabio Gasparri
- Nerviano Medical SciencesViale Pasteur, 10I-20014NervianoItaly
| | - Ivan Fraietta
- Nerviano Medical SciencesViale Pasteur, 10I-20014NervianoItaly
| | - Sonia Troiani
- Nerviano Medical SciencesViale Pasteur, 10I-20014NervianoItaly
| | - Daniela Arosio
- CNR, Istituto di Scienze e Tecnologie Molecolari (ISTM)Via C. Golgi, 19I-20133MilanItaly
| | - Laura Belvisi
- Università degli Studi di MilanoDipartimento di ChimicaVia C. Golgi, 19I-20133MilanItaly
- CNR, Istituto di Scienze e Tecnologie Molecolari (ISTM)Via C. Golgi, 19I-20133MilanItaly
| | - Luca Pignataro
- Università degli Studi di MilanoDipartimento di ChimicaVia C. Golgi, 19I-20133MilanItaly
| | - Alberto Dal Corso
- Università degli Studi di MilanoDipartimento di ChimicaVia C. Golgi, 19I-20133MilanItaly
| | - Cesare Gennari
- Università degli Studi di MilanoDipartimento di ChimicaVia C. Golgi, 19I-20133MilanItaly
- CNR, Istituto di Scienze e Tecnologie Molecolari (ISTM)Via C. Golgi, 19I-20133MilanItaly
| |
Collapse
|
23
|
Porubský M, Gurská S, Stanková J, Hajdúch M, Džubák P, Hlaváč J. Amino-BODIPY as the ratiometric fluorescent sensor for monitoring drug release or “power supply” selector for molecular electronics. RSC Adv 2019; 9:25075-25083. [PMID: 35528670 PMCID: PMC9069925 DOI: 10.1039/c9ra03472b] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2019] [Accepted: 07/28/2019] [Indexed: 01/06/2023] Open
Abstract
The glutathione cleavable conjugates of amino-BODIPY dye with model drugs have been tested for monitoring the drug release via ratiometric fluorescence based on two excitation and one emission wavelength. As a self-immolative linker was used for the construction of conjugates, free amino-BODIPY was released with the drug. Different excitation profiles of the dye before and after conjugate cleavage and similar emission wavelengths that enabled monitoring the release of the drug via the OFF–ON effect were successfully tested inside the cancer cells. UV/Vis spectrometry could be used in the quantification of the conjugate/drug in an analyte irrespective of the cleavage grade. As the system functionality was based only on the altered acylamino-BODIPY present in the conjugate to amino-BODIPY released during the cleavage, the method could be applied as a ratiometric fluorescence theranostic system to other non-fluorescent drugs. Moreover, the present conjugates demonstrated their potential application in molecular electronics as a “power supply” selector enabling the application of two power sources for one “bulb” to maintain its light intensity. Amino-BODIPY as the universal and highly fluorescent OFF–ON and ratiometric sensor for thiol-mediated drug release monitoring.![]()
Collapse
Affiliation(s)
- Martin Porubský
- Department of Organic Chemistry
- Faculty of Science
- Palacký University
- 771 46 Olomouc
- Czech Republic
| | - Soňa Gurská
- Institute of Molecular and Translational Medicine
- Faculty of Medicine and Dentistry
- Palacký University
- Olomouc
- Czech Republic
| | - Jarmila Stanková
- Institute of Molecular and Translational Medicine
- Faculty of Medicine and Dentistry
- Palacký University
- Olomouc
- Czech Republic
| | - Marián Hajdúch
- Institute of Molecular and Translational Medicine
- Faculty of Medicine and Dentistry
- Palacký University
- Olomouc
- Czech Republic
| | - Petr Džubák
- Institute of Molecular and Translational Medicine
- Faculty of Medicine and Dentistry
- Palacký University
- Olomouc
- Czech Republic
| | - Jan Hlaváč
- Department of Organic Chemistry
- Faculty of Science
- Palacký University
- 771 46 Olomouc
- Czech Republic
| |
Collapse
|
24
|
Cinelli MA. Topoisomerase 1B poisons: Over a half-century of drug leads, clinical candidates, and serendipitous discoveries. Med Res Rev 2018; 39:1294-1337. [PMID: 30456874 DOI: 10.1002/med.21546] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2018] [Revised: 10/08/2018] [Accepted: 10/09/2018] [Indexed: 12/17/2022]
Abstract
Topoisomerases are DNA processing enzymes that relieve supercoiling (torsional strain) in DNA, are necessary for normal cellular division, and act by nicking (and then religating) DNA strands. Type 1B topoisomerase (Top1) is overexpressed in certain tumors, and the enzyme has been extensively investigated as a target for cancer chemotherapy. Various chemical agents can act as "poisons" of the enzyme's religation step, leading to Top1-DNA lesions, DNA breakage, and eventual cellular death. In this review, agents that poison Top1 (and have thus been investigated for their anticancer properties) are surveyed, including natural products (such as camptothecins and indolocarbazoles), semisynthetic camptothecin and luotonin derivatives, and synthetic compounds (such as benzonaphthyridines, aromathecins, and indenoisoquinolines), as well as targeted therapies and conjugates. Top1 has also been investigated as a therapeutic target in certain viral and parasitic infections, as well as autoimmune, inflammatory, and neurological disorders, and a summary of literature describing alternative indications is also provided. This review should provide both a reference for the medicinal chemist and potentially offer clues to aid in the development of new Top1 poisons.
Collapse
Affiliation(s)
- Maris A Cinelli
- Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan
| |
Collapse
|
25
|
Krishnan MA, Pandit A, Chelvam V. In Vivo Evaluation of Ligand Targeted Drug Conjugates for Cancer Therapy. ACTA ACUST UNITED AC 2018; 10:e49. [PMID: 30212611 DOI: 10.1002/cpch.49] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
The development of small molecule ligand-targeted therapeutics is currently of paramount importance for treatment of cancer due to their potential to reduce system toxicity and increase potency of a delivered chemotherapeutic drug. The main aim of a targeted drug-delivery technique is to release the drug cargo selectively into tumor tissues, avoiding off-site toxicity to healthy tissues and organs during chemotherapy. In this strategy, a chemotherapeutic drug is conjugated to a homing ligand, which has high affinity for proteins over-expressed on cancer cells, via a peptide linker and a self-immolative segment that facilitates intracellular release of drug cargo. During development of targeted drug conjugates, preclinical evaluation in tumor models of small animals like mice adds valuable data on the clinical performance of the drug. This article contains a set of protocols for implantation of tumor, determination of optimum dosage required for effective treatment, and estimation of maximum tolerated dose required for any visible side effects during treatment of cancer in tumor models of mice. © 2018 by John Wiley & Sons, Inc.
Collapse
Affiliation(s)
- Mena Asha Krishnan
- Discipline of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Simrol, Madhya Pradesh, India
| | - Amit Pandit
- Discipline of Chemistry, Indian Institute of Technology Indore, Simrol, Madhya Pradesh, India
| | - Venkatesh Chelvam
- Discipline of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Simrol, Madhya Pradesh, India.,Discipline of Chemistry, Indian Institute of Technology Indore, Simrol, Madhya Pradesh, India
| |
Collapse
|
26
|
Krishnan MA, Sengupta S, Chelvam V. Preparation of Ligand-Targeted Drug Conjugates for Cancer Therapy and Their Evaluation In Vitro. ACTA ACUST UNITED AC 2018; 10:e50. [PMID: 30212603 DOI: 10.1002/cpch.50] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Present treatment strategies focus on minimizing unwanted toxicity to healthy cells during chemotherapeutic treatment. This is achieved by developing strategies to selectively deliver drugs to malignant cells over-expressing specific protein biomarkers. The drugs are attached via a self-immolative linker to a small molecule homing ligand having affinity for protein biomarkers over-expressed during disease states. Several such targeting-ligand drug conjugates have now reached preclinical and clinical trials, and this article aims to show a general methodology to prepare the same. Using solid-phase peptide synthesis (SPPS) methodology, the targeting ligand is covalently linked to a peptide spacer having appropriate hydrophobic and hydrophilic amino acids. The targeting ligand-attached peptide spacer is next conjugated with the required drug molecule through a cleavable disulfide bond in a solution-phase reaction. This protocol further elucidates the step-by-step procedures to be followed for complete evaluation of newly synthesized ligand-targeted drug conjugates in vitro. © 2018 by John Wiley & Sons, Inc.
Collapse
Affiliation(s)
- Mena Asha Krishnan
- Discipline of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Simrol, Madhya Pradesh, India
| | - Sagnik Sengupta
- Discipline of Chemistry, Indian Institute of Technology Indore, Simrol, Madhya Pradesh, India
| | - Venkatesh Chelvam
- Discipline of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Simrol, Madhya Pradesh, India.,Discipline of Chemistry, Indian Institute of Technology Indore, Simrol, Madhya Pradesh, India
| |
Collapse
|
27
|
Wu J, Yuan J, Ye B, Wu Y, Xu Z, Chen J, Chen J. Dual-Responsive Core Crosslinking Glycopolymer-Drug Conjugates Nanoparticles for Precise Hepatocarcinoma Therapy. Front Pharmacol 2018; 9:663. [PMID: 30065648 PMCID: PMC6056621 DOI: 10.3389/fphar.2018.00663] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2018] [Accepted: 06/04/2018] [Indexed: 12/14/2022] Open
Abstract
Nanoparticles (NPs) have demonstrated a potential for hepatocarcinoma therapy. However, the effective and safe NP-mediated drug transportation is still challenging due to premature leakage and inaccurate release of the drug. Herein, we designed a series of core cross-linking galactose-based glycopolymer-drug conjugates (GPDs) NPs with both redox-responsive and pH-sensitive characteristics to target and program drug release. Glycopolymer is comprised of galactose-containing units, which gather on the surface of GPD NPs and exhibit specific recognition to hepatocarcinoma cells, which over-express the asialoglycoprotein receptor. GPD NPs are stable in a normal physiological environment and can rapidly release the drug in hepatocarcinoma cells, which are reductive and acidic, by combining disulfide bond cross-linked core, as well as boronate ester-linked hydrophilic glycopolymer chain and the hydrophobic drug.
Collapse
Affiliation(s)
| | | | | | | | | | - Jinghua Chen
- Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Pharmaceutical Sciences, Jiangnan University, Wuxi, China
| | - Jingxiao Chen
- Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Pharmaceutical Sciences, Jiangnan University, Wuxi, China
| |
Collapse
|
28
|
Lv Q, Yang X, Wang M, Yang J, Qin Z, Kan Q, Zhang H, Wang Y, Wang D, He Z. Mitochondria-targeted prostate cancer therapy using a near-infrared fluorescence dye–monoamine oxidase A inhibitor conjugate. J Control Release 2018; 279:234-242. [DOI: 10.1016/j.jconrel.2018.04.038] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2018] [Revised: 03/23/2018] [Accepted: 04/18/2018] [Indexed: 10/17/2022]
|
29
|
Patil Y, Shmeeda H, Amitay Y, Ohana P, Kumar S, Gabizon A. Targeting of folate-conjugated liposomes with co-entrapped drugs to prostate cancer cells via prostate-specific membrane antigen (PSMA). NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2018; 14:1407-1416. [DOI: 10.1016/j.nano.2018.04.011] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/26/2017] [Revised: 02/23/2018] [Accepted: 04/10/2018] [Indexed: 01/23/2023]
|
30
|
Pandit A, Sengupta S, Krishnan MA, Reddy RB, Sharma R, Venkatesh C. First report on 3D-QSAR and molecular dynamics based docking studies of GCPII inhibitors for targeted drug delivery applications. J Mol Struct 2018. [DOI: 10.1016/j.molstruc.2018.01.059] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
31
|
Lv Q, Yang J, Zhang R, Yang Z, Yang Z, Wang Y, Xu Y, He Z. Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate. Mol Pharm 2018; 15:1842-1852. [PMID: 29608845 DOI: 10.1021/acs.molpharmaceut.8b00026] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Prostate cancer (PCa) is the most prevalent cancer among men in the United States and remains the second-leading cause of cancer mortality in men. Paclitaxel (PTX) is the first line chemotherapy for PCa treatment, but its therapeutic efficacy is greatly restricted by the nonspecific distribution in vivo. Prostate-specific membrane antigen (PSMA) is overexpressed on the surface of most PCa cells, and its expression level increases with cancer aggressiveness, while being present at low levels in normal cells. The high expression level of PSMA in PCa cells offers an opportunity for target delivery of nonspecific cytotoxic drugs to PCa cells, thus improving therapeutic efficacy and reducing toxicity. PSMA has high affinity for DUPA, a glutamate urea ligand. Herein, a novel DUPA-PTX conjugate is developed using DUPA as the targeting ligand to deliver PTX specifically for treatment of PSMA expressing PCa. The targeting ligand DUPA enhances the transport capability and selectivity of PTX to tumor cells via PSMA mediated endocytosis. Besides, DUPA is conjugated with PTX via a disulfide bond, which facilitates the rapid and differential drug release in tumor cells. The DUPA-PTX conjugate exhibits potent cytotoxicity in PSMA expressing cell lines and induces a complete cessation of tumor growth with no obvious toxicity. Our findings give new insight into the PSMA-targeted delivery of chemotherapeutics and provide an opportunity for the development of novel active targeting drug delivery systems for PCa therapy.
Collapse
Affiliation(s)
- Qingzhi Lv
- School of Pharmacy , Binzhou Medical University , 346 Guanhai Road , Yantai 264003 , China
| | | | | | | | | | | | | | | |
Collapse
|
32
|
Sau S, Tatiparti K, Alsaab HO, Kashaw SK, Iyer AK. A tumor multicomponent targeting chemoimmune drug delivery system for reprograming the tumor microenvironment and personalized cancer therapy. Drug Discov Today 2018; 23:1344-1356. [PMID: 29551455 DOI: 10.1016/j.drudis.2018.03.003] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2017] [Revised: 02/11/2018] [Accepted: 03/09/2018] [Indexed: 02/06/2023]
Abstract
Nanoparticle library engineered with tunable size, shape, and geometry will provide a better idea of targeting multicomponent of tumor microenvironment consisting of epithelial cells, tumor hypoxia, tumor immune cells and angiogenic blood vessels.
Collapse
Affiliation(s)
- Samaresh Sau
- Use-inspired Biomaterials & Integrated Nano Delivery (U-BiND) Systems Laboratory, Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA.
| | - Katyayani Tatiparti
- Use-inspired Biomaterials & Integrated Nano Delivery (U-BiND) Systems Laboratory, Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA
| | - Hashem O Alsaab
- Use-inspired Biomaterials & Integrated Nano Delivery (U-BiND) Systems Laboratory, Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA; Department of Pharmaceutics and Pharmaceutical Technology, College of Pharmacy, Taif University, Taif, Saudi Arabia
| | - Sushil K Kashaw
- Department of Pharmaceutical Sciences, Dr Harisingh Gour Central University, Sagar, MP 470003, India
| | - Arun K Iyer
- Use-inspired Biomaterials & Integrated Nano Delivery (U-BiND) Systems Laboratory, Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA; Molecular Imaging Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA.
| |
Collapse
|
33
|
Krajčovičová S, Gucký T, Hendrychová D, Kryštof V, Soural M. A Stepwise Approach for the Synthesis of Folic Acid Conjugates with Protein Kinase Inhibitors. J Org Chem 2017; 82:13530-13541. [PMID: 29171753 DOI: 10.1021/acs.joc.7b02650] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Herein, we report an alternative synthetic approach for selected 2,6,9-trisubstituted purine CDK inhibitor conjugates with folic acid as a drug-delivery system targeting folate receptors. In contrast to the previously reported approaches, the desired conjugates were constructed stepwise using solid-phase synthesis starting from immobilized primary amines. The ability of the prepared conjugates to release the free drug was verified using dithiothreitol (DTT) and glutathione (GSH) as liberating agents. Finally, binding to the folate receptor (FOLR1) overexpressed in a cancer cell line was measured by flow cytometry using a fluorescent imaging probe.
Collapse
Affiliation(s)
- Soňa Krajčovičová
- Department of Organic Chemistry, Faculty of Science, Palacký University , Tr. 17. listopadu 12, 771 46 Olomouc, Czech Republic
| | - Tomáš Gucký
- Department of Chemical Biology and Genetics, Centre of the Region Haná for Biotechnological and Agricultural Research, Palacký University and Institute of Experimental Botany AS CR , Šlechtitelů 27, 78371 Olomouc, Czech Republic
| | - Denisa Hendrychová
- Laboratory of Growth Regulators, Centre of the Region Haná for Biotechnological and Agricultural Research, Palacký University and Institute of Experimental Botany AS CR , Šlechtitelů 27, 78371 Olomouc, Czech Republic
| | - Vladimír Kryštof
- Laboratory of Growth Regulators, Centre of the Region Haná for Biotechnological and Agricultural Research, Palacký University and Institute of Experimental Botany AS CR , Šlechtitelů 27, 78371 Olomouc, Czech Republic
| | - Miroslav Soural
- Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University , Hněvotínská 5, 779 00 Olomouc, Czech Republic
| |
Collapse
|
34
|
Xia L, Zeh R, Mizelle J, Newton A, Predina J, Nie S, Singhal S, Guzzo TJ. Near-infrared Intraoperative Molecular Imaging Can Identify Metastatic Lymph Nodes in Prostate Cancer. Urology 2017; 106:133-138. [PMID: 28438626 PMCID: PMC11090243 DOI: 10.1016/j.urology.2017.04.020] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2017] [Revised: 02/09/2017] [Accepted: 04/12/2017] [Indexed: 11/21/2022]
Abstract
OBJECTIVE To propose a novel method to perform indocyanine green (ICG) based near-infrared (NIR) fluorescence imaging during pelvic lymph node dissection (PLND) for prostate cancer patients with lymph node metastasis (LNM). MATERIALS AND METHODS A prostate cancer cell line PC3 was used to establish xenograft model in NOD/SCID mice. After tumor growth, the mice were injected with ICG through the tail vein. Xenografts and surrounding tissues were imaged with NIR camera 24 hours after intravenous ICG, and tumor-to-background ratios were calculated. We then performed a pilot human study to evaluate the role of NIR imaging in robotic PLND after systemic ICG in 4 patients with prostate cancer and preoperative lymphadenopathy. RESULTS ICG localized to PC3 xenografts in the mice and all xenografts were highly fluorescent compared with surrounding tissues, with a median tumor-to-background ratio of 2.85 (interquartile range = 2.64-3.90). In the human study, intraoperative in vivo NIR imaging identified 3 of the 4 preoperative lymphadenopathies as fluorescence-positive, and back table ex vivo NIR imaging identified all 4 lymphadenopathies as fluorescence-positive. All the lymphadenopathies were found to be LNMs by pathologic examination. Two of the four cases had additional LNMs, all of which were fluorescence-positive with intraoperative in vivo NIR imaging. CONCLUSION Intravenously administered ICG accumulates in prostate cancers in both a murine model and human patients. NIR fluorescence based on intravenous ICG may serve as a useful tool to facilitate the identification of positive nodes during PLND in patients with higher risk of LNMs.
Collapse
Affiliation(s)
- Leilei Xia
- Division of Urology, Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Center for Precision Surgery, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - Ryan Zeh
- Center for Precision Surgery, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Department of Neurosurgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - Jack Mizelle
- Center for Precision Surgery, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Division of Thoracic Surgery and Thoracic Surgery Research Laboratory, Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - Andrew Newton
- Center for Precision Surgery, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Division of Thoracic Surgery and Thoracic Surgery Research Laboratory, Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - Jarrod Predina
- Center for Precision Surgery, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Division of Thoracic Surgery and Thoracic Surgery Research Laboratory, Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - Shuming Nie
- Department of Biomedical Engineering, Emory University, Atlanta, GA
| | - Sunil Singhal
- Center for Precision Surgery, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Division of Thoracic Surgery and Thoracic Surgery Research Laboratory, Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - Thomas J Guzzo
- Division of Urology, Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Center for Precision Surgery, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
| |
Collapse
|
35
|
Pina A, Dal Corso A, Caruso M, Belvisi L, Arosio D, Zanella S, Gasparri F, Albanese C, Cucchi U, Fraietta I, Marsiglio A, Pignataro L, Donati D, Gennari C. Targeting Integrin αV
β3
with Theranostic RGD-Camptothecin Conjugates Bearing a Disulfide Linker: Biological Evaluation Reveals a Complex Scenario. ChemistrySelect 2017. [DOI: 10.1002/slct.201701052] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Affiliation(s)
- Arianna Pina
- Dipartimento di Chimica; Università degli Studi di Milano; Via C. Golgi 19 20133 Milano Italy
| | - A. Dal Corso
- Dipartimento di Chimica; Università degli Studi di Milano; Via C. Golgi 19 20133 Milano Italy
| | - Michele Caruso
- Nerviano Medical Sciences (NMS); Via Pasteur 10 20014 Nerviano Italy
| | - Laura Belvisi
- Dipartimento di Chimica; Università degli Studi di Milano; Via C. Golgi 19 20133 Milano Italy
| | - Daniela Arosio
- Istituto di Scienze e Tecnologie Molecolari (ISTM); CNR; Via C. Golgi 19 20133 Milano Italy
| | - Simone Zanella
- Dipartimento di Chimica; Università degli Studi di Milano; Via C. Golgi 19 20133 Milano Italy
| | - Fabio Gasparri
- Nerviano Medical Sciences (NMS); Via Pasteur 10 20014 Nerviano Italy
| | - Clara Albanese
- Nerviano Medical Sciences (NMS); Via Pasteur 10 20014 Nerviano Italy
| | - Ulisse Cucchi
- Nerviano Medical Sciences (NMS); Via Pasteur 10 20014 Nerviano Italy
| | - Ivan Fraietta
- Nerviano Medical Sciences (NMS); Via Pasteur 10 20014 Nerviano Italy
| | - Aurelio Marsiglio
- Nerviano Medical Sciences (NMS); Via Pasteur 10 20014 Nerviano Italy
| | - Luca Pignataro
- Dipartimento di Chimica; Università degli Studi di Milano; Via C. Golgi 19 20133 Milano Italy
| | - Daniele Donati
- Nerviano Medical Sciences (NMS); Via Pasteur 10 20014 Nerviano Italy
| | - Cesare Gennari
- Dipartimento di Chimica; Università degli Studi di Milano; Via C. Golgi 19 20133 Milano Italy
| |
Collapse
|
36
|
Slatkovská B, Ondriaš J, Doháňošová J, Gracza T, Babjak M. Facile Access to Amino Acid Substituted Indenoisoquinolines through Carbonylative Cycloamination with [Fe(CO)5
]. ChemistrySelect 2017. [DOI: 10.1002/slct.201700825] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Affiliation(s)
- Beáta Slatkovská
- Department of Organic Chemistry; Slovak University of Technology in Bratislava; Radlinského 9 SK-81237 Bratislava
| | - Jakub Ondriaš
- Department of Organic Chemistry; Slovak University of Technology in Bratislava; Radlinského 9 SK-81237 Bratislava
| | - Jana Doháňošová
- Central Laboratories; Slovak University of Technology in Bratislava; Radlinského 9 SK-81237 Bratislava
| | - Tibor Gracza
- Department of Organic Chemistry; Slovak University of Technology in Bratislava; Radlinského 9 SK-81237 Bratislava
| | - Matej Babjak
- Department of Organic Chemistry; Slovak University of Technology in Bratislava; Radlinského 9 SK-81237 Bratislava
| |
Collapse
|
37
|
Evans JC, Malhotra M, Cryan JF, O'Driscoll CM. The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease. Br J Pharmacol 2016; 173:3041-3079. [PMID: 27526115 PMCID: PMC5056232 DOI: 10.1111/bph.13576] [Citation(s) in RCA: 65] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2016] [Revised: 07/08/2016] [Accepted: 07/25/2016] [Indexed: 12/11/2022] Open
Abstract
Prostate specific membrane antigen (PSMA) otherwise known as glutamate carboxypeptidase II (GCPII) is a membrane bound protein that is highly expressed in prostate cancer and in the neovasculature of a wide variety of tumours including glioblastomas, breast and bladder cancers. This protein is also involved in a variety of neurological diseases including schizophrenia and ALS. In recent years, there has been a surge in the development of both diagnostics and therapeutics that take advantage of the expression and activity of PSMA/GCPII. These include gene therapy, immunotherapy, chemotherapy and radiotherapy. In this review, we discuss the biological roles that PSMA/GCPII plays, both in normal and diseased tissues, and the current therapies exploiting its activity that are at the preclinical stage. We conclude by giving an expert opinion on the future direction of PSMA/GCPII based therapies and diagnostics and hurdles that need to be overcome to make them effective and viable.
Collapse
Affiliation(s)
- James C Evans
- Pharmacodelivery Group, School of Pharmacy, University College Cork, Cork, Ireland
| | - Meenakshi Malhotra
- Pharmacodelivery Group, School of Pharmacy, University College Cork, Cork, Ireland
| | - John F Cryan
- Department of Anatomy and Neuroscience, University College Cork, Cork, Ireland
| | | |
Collapse
|
38
|
A Novel Prostate-Specific Membrane-Antigen (PSMA) Targeted Micelle-Encapsulating Wogonin Inhibits Prostate Cancer Cell Proliferation via Inducing Intrinsic Apoptotic Pathway. Int J Mol Sci 2016; 17:ijms17050676. [PMID: 27196894 PMCID: PMC4881502 DOI: 10.3390/ijms17050676] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2016] [Revised: 04/21/2016] [Accepted: 04/25/2016] [Indexed: 02/05/2023] Open
Abstract
Prostate cancer (PCa) is a malignant tumor for which there are no effective treatment strategies. In this study, we developed a targeted strategy for prostate-specific membrane-antigen (PSMA)-positive PCa in vitro based on 2-(3-((S)-5-amino-1-carboxypentyl)ureido) pentanedioic acid (ACUPA) modified polyethylene glycol (PEG)-Cholesterol micelles containing wogonin (WOG), which was named ACUPA-M-WOG. ACUPA-M-WOG was conventionally prepared using a self-assembling method, which produced stable particle size and ζ potential. Moreover, ACUPA-M-WOG showed good drug encapsulating capacity and drug release profiles. Fluorescence activated cell sorting (FACS) results suggested that ACUPA modified PEG-Cholesterol micelles could effectively enhance the drug uptake on PSMA(+) PCa cells, and the cytotoxicity of ACUPA-M-WOG was stronger than other controls according to in vitro cellular proliferation and apoptosis assays, separately through methyl thiazolyl tetrazolium (MTT) and Annexin V/Propidium Iodide (PI) staining. Finally, the molecular mechanisms of ACUPA-M-WOG’s effects on human PSMA(+) PCa were investigated, and were mainly the intrinsic or extrinsic apoptosis signaling pathways. The Western blot results suggested that ACUPA-M-WOG could enhance the WOG-induced apoptosis, which was mainly via the intrinsic signaling pathway rather than the extrinsic signaling pathway. In conclusion, ACUPA-M-WOG was successfully developed for WOG-selective delivery to PSMA(+) PCa cells and had stronger inhibition than free drugs, which might make it an effective strategy for PSMA(+) PCa.
Collapse
|
39
|
Machulkin AE, Ivanenkov YA, Aladinskaya AV, Veselov MS, Aladinskiy VA, Beloglazkina EK, Koteliansky VE, Shakhbazyan AG, Sandulenko YB, Majouga AG. Small-molecule PSMA ligands. Current state, SAR and perspectives. J Drug Target 2016; 24:679-93. [DOI: 10.3109/1061186x.2016.1154564] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Affiliation(s)
- Alexey E. Machulkin
- Moscow State University, Chemistry Dept, Leninskie Gory, Moscow, Russian Federation
- National University of Science and Technology MISiS, Moscow, Russian Federation
| | - Yan A. Ivanenkov
- Moscow State University, Chemistry Dept, Leninskie Gory, Moscow, Russian Federation
- National University of Science and Technology MISiS, Moscow, Russian Federation
- Moscow Institute of Physics and Technology (State University), Dolgoprudny City, Russian Federation
| | - Anastasia V. Aladinskaya
- Moscow Institute of Physics and Technology (State University), Dolgoprudny City, Russian Federation
| | - Mark S. Veselov
- Moscow Institute of Physics and Technology (State University), Dolgoprudny City, Russian Federation
| | - Vladimir A. Aladinskiy
- Moscow Institute of Physics and Technology (State University), Dolgoprudny City, Russian Federation
| | | | - Victor E. Koteliansky
- Moscow State University, Chemistry Dept, Leninskie Gory, Moscow, Russian Federation
- Skolkovo Institute of Science and Technology “Scoltech”, Novaya, Russian Federation
| | - Artem G. Shakhbazyan
- Moscow Institute of Physics and Technology (State University), Dolgoprudny City, Russian Federation
| | - Yuri B. Sandulenko
- Moscow Institute of Physics and Technology (State University), Dolgoprudny City, Russian Federation
| | - Alexander G. Majouga
- Moscow State University, Chemistry Dept, Leninskie Gory, Moscow, Russian Federation
- National University of Science and Technology MISiS, Moscow, Russian Federation
| |
Collapse
|